Taniborbactam

Taniborbactam
Clinical data
Other names	VNRX-5133, VNRX5133
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (3R)-3-[[2-[4-(2-Aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid;
CAS Number	1613267-49-4;
PubChem CID	76902493;
ChemSpider	115037173;
UNII	8IGQ156Z07;
KEGG	D11718;
ChEMBL	ChEMBL4463697;
Chemical and physical data
Formula	C19H28BN3O5
Molar mass	389.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES B1([C@H](CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O;
	InChI InChI=InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1; Key:PFZUWUXKQPRWAL-PXCJXSSVSA-N;

Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor.^[1] It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.^[2]

Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.^[3]^[4]

References

^ Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, et al. (March 2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.
^ Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (April 2023). "NDM-9 resistance to taniborbactam". The Lancet. Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.
^ Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. (February 2024). "Cefepime-Taniborbactam in Complicated Urinary Tract Infection". The New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.
^ "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, et al. (March 2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.

[2] Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (April 2023). "NDM-9 resistance to taniborbactam". The Lancet. Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.

[3] Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. (February 2024). "Cefepime-Taniborbactam in Complicated Urinary Tract Infection". The New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.

[4] "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.

[1]

[2]

[3]

[4]